Logo image of MBX

MBX BIOSCIENCES INC (MBX) Stock Price, Quote, News and Overview

NASDAQ:MBX - Nasdaq - US55287L1017 - Currency: USD

10.88  -0.95 (-8.03%)

After market: 10.88 0 (0%)

MBX Quote, Performance and Key Statistics

MBX BIOSCIENCES INC

NASDAQ:MBX (2/21/2025, 8:00:01 PM)

After market: 10.88 0 (0%)

10.88

-0.95 (-8.03%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week HighN/A
52 Week LowN/A
Market Cap363.61M
Shares33.42M
Float22.54M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO09-13 2024-09-13


MBX short term performance overview.The bars show the price performance of MBX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 -40

MBX long term performance overview.The bars show the price performance of MBX in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of MBX is 10.88 USD. In the past month the price decreased by -7.25%.

MBX BIOSCIENCES INC / MBX Daily stock chart

MBX Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 67.21 829.40B
NVO NOVO-NORDISK A/S-SPONS ADR 27.53 390.99B
JNJ JOHNSON & JOHNSON 16.25 390.76B
AZN ASTRAZENECA PLC-SPONS ADR 20.56 230.17B
MRK MERCK & CO. INC. 11.71 226.40B
NVS NOVARTIS AG-SPONSORED ADR 13.77 215.98B
PFE PFIZER INC 8.46 149.04B
SNY SANOFI-ADR 13.62 136.54B
BMY BRISTOL-MYERS SQUIBB CO 48.97 113.23B
GSK GSK PLC-SPON ADR 7.81 74.77B
ZTS ZOETIS INC 27.1 72.39B
TAK TAKEDA PHARMACEUTIC-SP ADR 31.95 44.58B

About MBX

Company Profile

MBX Biosciences Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Carmel, Indiana and currently employs 36 full-time employees. The company went IPO on 2024-09-13. MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company has built its proprietary Precision Endocrine Peptide platform to develop precision peptide therapies that are designed to overcome key limitations of current peptide therapies. Its product candidates and programs include MBX 2109, MBX 1416 and Obesity portfolio. MBX 2109 is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. MBX 1416 is designed to be a long-acting glucagon-like peptide-1 (GLP-1), receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. MBX 4291 is designed to be a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide, receptor co-agonist prodrug.

Company Info

MBX BIOSCIENCES INC

12406 Horesham Street

Carmel INDIANA US

Employees: 36

Company Website: https://mbxbio.com/

Phone: 13179893100

MBX BIOSCIENCES INC / MBX FAQ

What is the stock price of MBX BIOSCIENCES INC today?

The current stock price of MBX is 10.88 USD. The price decreased by -8.03% in the last trading session.


What is the ticker symbol for MBX BIOSCIENCES INC stock?

The exchange symbol of MBX BIOSCIENCES INC is MBX and it is listed on the Nasdaq exchange.


On which exchange is MBX stock listed?

MBX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for MBX BIOSCIENCES INC stock?

8 analysts have analysed MBX and the average price target is 37.99 USD. This implies a price increase of 249.22% is expected in the next year compared to the current price of 10.88. Check the MBX BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is MBX BIOSCIENCES INC worth?

MBX BIOSCIENCES INC (MBX) has a market capitalization of 363.61M USD. This makes MBX a Small Cap stock.


How many employees does MBX BIOSCIENCES INC have?

MBX BIOSCIENCES INC (MBX) currently has 36 employees.


What are the support and resistance levels for MBX BIOSCIENCES INC (MBX) stock?

MBX BIOSCIENCES INC (MBX) has a resistance level at 12.35. Check the full technical report for a detailed analysis of MBX support and resistance levels.


Should I buy MBX BIOSCIENCES INC (MBX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does MBX BIOSCIENCES INC (MBX) stock pay dividends?

MBX does not pay a dividend.


What is the Price/Earnings (PE) ratio of MBX BIOSCIENCES INC (MBX)?

MBX BIOSCIENCES INC (MBX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.46).


What is the Short Interest ratio of MBX BIOSCIENCES INC (MBX) stock?

The outstanding short interest for MBX BIOSCIENCES INC (MBX) is 12.42% of its float. Check the ownership tab for more information on the MBX short interest.


MBX Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

MBX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to MBX. While MBX has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MBX Financial Highlights

Over the last trailing twelve months MBX reported a non-GAAP Earnings per Share(EPS) of -2.46. The EPS decreased by -24.39% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -27.94%
ROE -29.07%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)-24.39%
Revenue 1Y (TTM)N/A

MBX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 88% to MBX. The Buy consensus is the average rating of analysts ratings from 8 analysts.


Ownership
Inst Owners69.31%
Ins Owners3.24%
Short Float %12.42%
Short Ratio8.56
Analysts
Analysts87.5
Price Target37.99 (249.17%)
EPS Next Y-1033.77%
Revenue Next YearN/A